Clinical trials: Vaccine Prophylaxis
Monkeypox (Mpox)
Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections
All participants will receive 2 vaccinations of the same dose of Modified Vaccinia Ankara Virus (MVA-BN) vaccine 4 weeks apart (standard regimen).
- Trial name
- NCT06549530
- Testing
- MVA-BN
- Where
- 3 sites in Democratic Republic of the Congo, Uganda
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Norovirus Infections, Norovirus Gastroenteritis
A Study to Evaluate INT101 in Healthy Adults for the Prevention of Norovirus Gastroenteritis
This study is being conducted to evaluate the safety and immunogenicity of INT101, an investigational vaccine intended to prevent norovirus gastroenteritis, in healthy adults.
- Trial name
- INT-101 (NCT07818629)
- Testing
- INT101 Low Dose, INT101 High Dose
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- InThera Inc. Korea
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.
The purpose of this study is to evaluate the immunogenicity and safety of 13-valent pneumococcal polysaccharide vaccine when given concomitantly with seasonal inactivated influenza vaccine to adults 50 years and older who have…
- Trial name
- NCT02124161
- Testing
- 13-valent pneumococcal conjugate vaccine, Seasonal Inactivated Influenza Vaccine
- Where
- 44 sites in United States
- Volunteers
- 882 people, healthy volunteers welcome
- Sponsor
- Pfizer
Tetanus, Hepatitis B
Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infants
The primary purpose of this study is to demonstrate the lot-to-lot consistency of 3 production lots of GSK Biologicals' Hib-MenAC (Haemophilus influenzae type b and meningococcal serogroups A and C) vaccine when reconstituted…
- Conditions
- Tetanus, Hepatitis B, Haemophilus Influenzae Type b, Whole Cell Pertussis
- Trial name
- NCT00197275
- Testing
- Hib-MenAC mixed with Tritanrix™-HepB
- Where
- 3 sites in Thailand
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prophylaxis for the Measles Infection
A Clinical Trial to Assess the Safety of a Measles Vaccine (Dry Powder) Administered by Two Different Devices
This is a phase I, open-label, randomized study in healthy adults. Eligible subjects will be given single dose of either Dry Powdered Measles Vaccine (PMV) by Puffhaler® device, Dry PMV by SoloventTM device or licensed measles…
- Trial name
- PMV-001 (NCT01557699)
- Testing
- PMV via Puffhaler® device, PMV via SoloventTM device, Licensed Subcutaneous Measles Vaccine
- Where
- India
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Diphtheria, Tetanus
Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine
A randomized phase IV study of the liquid pentavalent combination vaccine to evaluate the safety, immunogenicity (short term and long term) and clinical consistency of three production lots of the vaccine.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT00877357
- Testing
- Shan 5
- Where
- India
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Shantha Biotechnics Limited
HIV-1
Investigation of the Safety of an HIV-1 Vaccine Given Intra-muscularly and Intra-nasally to Healthy Female Subjects
This study is designed to investigate the safety and efficacy of a newly developed vaccine against HIV-1 in female healthy subjects.
- Trial name
- NCT01084343
- Testing
- MYM-V101
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mymetics Corporation
Malaria
A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria
This was a randomized, dose-escalation Phase I/IIa study to evaluate safety, tolerability, immunogenicity and efficacy of an investigational RNA-based vaccine (BNT165e) for prevention of P.
- Trial name
- NCT06069544
- Testing
- BNT165c, BNT165d
- Where
- 5 sites in United States
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Yellow Fever, Rabies
A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults
The purpose of this first time in humans trial is to evaluate the safety, reactogenicity and immunogenicity of AVX70120 and of AVX70481 in healthy participants.
- Trial name
- SAFYR (NCT06998004)
- Testing
- AVX70120 low dose level, AVX70120 middle dose level, AVX70120 high dose level
- Where
- 2 sites in Belgium
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- AstriVax Therapeutics
Meningitis, Meningococcal, Rotavirus Infections
RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)
Primary objective: To check if RotaTeq® can be administered concomitantly with meningococcal Group C vaccine without impairing the efficacy of MCC vaccine.
- Trial name
- NCT00443846
- Testing
- RotaTeq®, NeisVac-C®
- Volunteers
- 247 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Prevention
Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults
The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of polyvalent env (A,B,C,A/E)/gag (C) DNA prime and gp120 (A,B,C,A/E) protein HIV-1 vaccines boost (PDPHV) with either Alhydrogel or GLA-SE in…
- Trial name
- NCT07675629
- Testing
- PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant
- Where
- 2 sites in United States, South Africa
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Worcester HIV Vaccine
Sars-CoV-2 Infection
Safety, Tolerability and Immunogenicity of Alveavax-v1.2, a BA.2/Omicron-optimized, DNA Vaccine for COVID-19 Prevention
The investigated product is a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Booster Vaccine candidate optimized for the Omicron/BA.2 variant.
- Trial name
- NCT05844202
- Testing
- Alveavax-v1.2, Janssen Ad26.COV2.S
- Where
- 8 sites in South Africa
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Alvea Holdings, LLC
Cytomegalovirus (CMV) Infections
V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)
This study evaluated the safety, tolerability, and efficacy of the cytomegalovirus (CMV) vaccine (V160) administered in a 2-dose or 3-dose regimen to healthy seronegative women 16 to 35 years of age.
- Trial name
- NCT03486834
- Testing
- V160
- Where
- 95 sites in United States, Australia and 5 more
- Volunteers
- 2,200 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Virus Diseases
A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens in Chinese Children
The purpose of this study is to evaluate the 1 year immunogenicity persistence of Rabipur in children 6-17 years of age, and compare the Zagreb regimen with the Essen regimen.
- Trial name
- NCT03192371
- Testing
- Rabipur
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19 Prevention
Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Phase II/III Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for SARS-Сov-2 Infection in Indian…
- Trial name
- NCT04640233
- Testing
- Gam-COVID-Vac
- Where
- 23 sites in India
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Infections, Meningococcal
Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants
The purpose of this primary vaccination study is to evaluate the immunogenicity, safety and reactogenicity of three doses of GSK Biologicals' MenC-TT (Neisseria meningitidis group C polysaccharide-tetanus toxoid) vaccine (2…
- Trial name
- NCT00135486
- Testing
- MenC-TT, Hib-MenC-TT
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza Prevention
Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine
To evaluate the protective effect 14 days after the live attenuated influenza vaccine; To evaluate the protective effect of vaccination with live attenuated influenza vaccine; To evaluate the safety of freeze-dried nasal spray…
- Trial name
- NCT06280144
- Testing
- Influenza Vaccine, Live, Nasal, Freeze-dried, Sterile water for inhalation
- Where
- China
- Volunteers
- 6,080 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Influenza
Incidence of Influenza, Downstream Complications of Influenza & Hospitalizations in Elderly Vaccinated With Fluarix™
This study will investigate the incidence of influenza, disease and various possible downstream complications and hospitalizations or emergency room visits after routine annual vaccination of the elderly population with Fluarix™.
- Trial name
- NCT00306982
- Testing
- Fluarix
- Where
- 12 sites in Australia, Brazil
- Volunteers
- 1,524 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Covid-19 Prevention
A Study of Ad26.COV2.S in Adults (COVID-19)
The purpose of the study is to assess the safety, reactogenicity, and immunogenicity of Ad26.COV2.S at 2 dose levels, administered intramuscularly (IM) as a single-dose or 2-dose schedule, with a single booster vaccination…
- Trial name
- NCT04436276
- Testing
- Ad26.COV2.S
- Where
- 12 sites in United States, Belgium
- Volunteers
- 1,085 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
COVID-19
Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19
This is a phase 2 randomized, double-blind clinical trial testing an anti-SARS-CoV-2 COVID-19 vaccine (AV-COVID-19) made on site using PT AIVITA Biomedika Indonesia's vaccine-enabling kit for the prevention of COVID-19 infection.
- Trial name
- NCT05007496
- Testing
- AV-COVID-19
- Where
- Indonesia
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Aivita Biomedical, Inc.